Years before a Parkinson’s diagnosis — sometimes as many as two decades before tremors appear — the disease already seems to be announcing itself in a strange, easy-to-miss way: constipation and disrupted sleep. Scientists have increasingly come to suspect the explanation isn’t just in the gut itself, but in what’s living there, and a handful of recent trials are now testing whether fixing the gut can actually help.
Key Takeaways
- A 2024 study comparing gut bacteria in Parkinson’s patients across four countries found consistently disrupted pathways for producing B vitamins, specifically riboflavin (B2) and biotin (B7).
- Two separate randomized, placebo-controlled trials — one in Belgium, one in China — found fecal microbiota transplants (FMT) improved motor symptoms in Parkinson’s patients more than a placebo did.
- Not every FMT study has found a benefit: a smaller pilot study using a different transplant method found no significant improvement in motor symptoms, underscoring that results vary by trial design.
- All of this remains early-stage research. The trials are small, mostly phase 2, and researchers are explicit that larger studies are needed before this becomes standard treatment.
The B Vitamin Connection
In 2024, a team led by Hiroshi Nishiwaki at Nagoya University in Japan compared fecal samples from 94 people with Parkinson’s disease to 73 without it, then checked their findings against separate datasets from China, Taiwan, Germany, and the US. Despite each country having a different overall mix of gut bacteria, the same disrupted pathway kept showing up in Parkinson’s patients: reduced capacity to produce riboflavin and biotin. The team linked this deficiency to lower levels of short-chain fatty acids and polyamines, molecules that help maintain a healthy mucus layer in the intestines.
“Deficiencies in polyamines and SCFAs could lead to thinning of the intestinal mucus layer, increasing intestinal permeability, both of which have been observed in Parkinson’s disease,” Nishiwaki explained.
The theory is that a weakened gut barrier allows more exposure to everyday toxins, potentially contributing to the abnormal clumping of a protein called alpha-synuclein — the same protein buildup thought to drive Parkinson’s slow progression toward tremors and rigidity.
“Supplementation therapy targeting riboflavin and biotin holds promise as a potential therapeutic avenue,” Nishiwaki said when the study was published, while also noting this remains an investigational idea rather than an established treatment.
What the Fecal Transplant Trials Found
Two separate randomized, placebo-controlled trials have tested a more direct intervention: transplanting stool from a healthy donor into a Parkinson’s patient’s gut. In Belgium, the GUT-PARFECT trial gave 46 people with mild-to-moderate Parkinson’s either a donor transplant or their own stool as a placebo. After 12 months, the donor group’s motor symptom score (measured on the standard MDS-UPDRS scale) improved by 5.8 points, compared to 2.7 points in the placebo group, with the biggest gains appearing between six and twelve months.
“After 12 months, participants who received the healthy donor stool transplant showed a significant improvement in their motor score,” said gastroenterologist Arnout Bruggeman of Ghent University Hospital, who led the trial.
A larger, more recent trial out of Zhengzhou University in China, published this year, gave 72 newly diagnosed, treatment-naive patients either repeated donor transplants or their own stool across three rounds. After 35 weeks, the donor group’s motor scores improved by an average of 3.8 points, while the control group’s symptoms slightly worsened. Nearly half the donor group saw a clinically meaningful improvement, compared to about a fifth of the control group — and researchers also observed potentially harmful bacteria like E. coli and Shigella becoming less abundant, along with lower alpha-synuclein levels in the gut, tying back to the same protein flagged in the earlier B-vitamin research.
Not Every Trial Has Found a Benefit
It’s worth noting the evidence isn’t uniformly positive. A separate open-label pilot study of 12 patients, which delivered FMT via enema rather than the nasojejunal tube method used in the Belgian trial, found no significant change in motor symptoms overall, though it did note a trend toward reduced “off” time (periods when Parkinson’s medication isn’t working well). A broader systematic review pooling multiple FMT trials found a generally positive safety profile and improvement in motor scores and constipation, but explicitly called for larger, standardized multicenter trials before drawing firm conclusions — a sign the field sees this as promising but unsettled, not proven.
What This Means Right Now
None of this represents an approved or ready-to-use Parkinson’s treatment. The trials so far are small, mostly early-phase, and use different transplant delivery methods with somewhat different results. Fecal transplants specifically carry real practical and regulatory hurdles before wider use, and researchers involved in this work are framing it as a proof of concept — evidence that gut bacteria genuinely influence Parkinson’s symptoms — rather than a treatment anyone should pursue outside a clinical trial. As Nishiwaki put it, the long-term goal is more targeted: identifying which patients have specific vitamin deficiencies and treating those deficiencies directly, potentially through simple oral supplementation, rather than a full microbiome transplant for everyone.
Sources: Nishiwaki, H., et al. (2024). Gut microbiota in Parkinson’s disease. npj Parkinson’s Disease; Bruggeman, A., et al. (2024). GUT-PARFECT trial. eClinicalMedicine; Zhengzhou University team (2026). Signal Transduction and Targeted Therapy; ScienceAlert, “Parkinson’s Link to Gut Bacteria Hints at Unexpectedly Simple Treatment” (Aug. 18, 2026).